Healthcare executives are accustomed to seeing prior authorization failures in denial rates, accounts receivable (A/R) days, appeal volume, and write-offs. Those measures are essential, but they reveal the problem after the healthcare provider has already absorbed administrative cost, disrupted clinical capacity, or delivered care without secure reimbursement.
Prior authorization turnaround time offers an earlier view. It shows where payer complexity and internal friction affect both care and cash while leaders still have choices. Yet speed alone can be misleading. An authorization secured quickly can still leave revenue exposed if it covers the wrong code, units, rendering provider, site of service, or date range. The executive question is whether the healthcare provider can move from order to care with speed, submission quality, and continuity through billing.
Why Turnaround Time Is an Early Revenue Signal
Prior authorization turnaround time is more than a patient access productivity measure. It is an enterprise leading indicator. Each unresolved day leaves patient care, scheduled capacity, and expected revenue uncertain.
Turnaround time serves as a front-end correlation to A/R days. Just as A/R days reveal how long revenue remains outstanding after care has been delivered, authorization aging reveals how long access, capacity, and reimbursement remain uncertain before care. This earlier signal gives leaders time to intervene before the risk becomes a denial, schedule disruption, or write-off.
The question is not simply whether authorization teams are processing requests quickly. It is whether leaders can identify where risk is concentrated by payer, service line, clinical urgency, and financial exposure, and whether accountability is clear when cases approach the scheduled date unresolved.
Measure Speed, Quality, and Continuity
For reporting, turnaround time needs a consistent definition. Decide whether timing begins at order entry, intake, or receipt of a complete request and whether it ends at the initial response or final payer determination. Without a common definition, enterprise averages can combine very different operational realities.
Turnaround time should then be read alongside two other performance dimensions:
- Submission quality. First-pass approval, pended request rate, missing information rate, and medical necessity denial rates show whether requests are accurate, complete, and payer-ready.
- End-to-end continuity. Authorization status at the service date, treatment delays, reschedules, and authorization-to-claim mismatches show whether the approval remained useful through care delivery and billing.
Averages should be segmented by payer, service, financial exposure, and proximity to the scheduled date. Otherwise, acceptable enterprise performance can mask a small number of high-value or clinically urgent cases that carry disproportionate risk. Viewed together, speed, quality, and continuity help executives distinguish a productive queue from a reliable revenue cycle operating model.
Four Intervals for the Authorization Clock
A single turnaround-time number can hide where delay accumulates. Leaders need a clock that separates each stage and assigns accountability without confusing payer response time with internal preparation time.
- Order-to-intake latency. Time between order entry and arrival in the authorization queue reveals routing gaps, missing intake information, and work that has not yet reached the team responsible for clearance.
- Request-preparation time. Time spent validating coverage, codes, clinical evidence, and payer requirements shows how long the healthcare provider needs to produce a complete submission.
- Payer decision time. Elapsed time from complete submission to payer determination isolates the portion of the clock governed primarily by payer response and follow-up requirements.
- Post-decision resolution time. Time spent answering pends, correcting partial approvals, arranging peer-to-peer review, or resolving an unusable determination shows whether a payer response actually clears the case for care.
Translating Financial and Capacity Insights
Unresolved authorizations should be evaluated alongside the scheduled service date, expected reimbursement, service-line capacity, clinical urgency, and likelihood of rescheduling. The same number of elapsed days can carry very different implications across a routine study, a high-cost infusion, and a complex surgical case.
A useful view shows the expected revenue awaiting clearance, the number and value of cases approaching the service date without a usable determination, and the clinical capacity that may be disrupted. It should also distinguish isolated exceptions from persistent patterns by payer and services.
This framing connects authorization friction to decisions about capacity, payer strategy, staffing, and investment. It gives executives a financial and operational signal without requiring them to manage the detailed workflow.
Turn Authorization Intelligence into Design Decisions
Breaking prior authorization turnaround time into meaningful intervals helps identify where risk is accumulating. Connecting those intervals to scheduled services, expected reimbursement, clinical capacity, and proximity to care shows which problems warrant leadership attention.
A sustainable model should inform four key decisions to ensure assignments are completed and services remain aligned:
- Prioritize the risk. Determine which payers, service lines, and categories of authorization delay create the greatest financial, capacity, or patient-access exposure.
- Set the investment level. Decide where additional expertise, technology, automation, or external support is justified by the concentration and business impact of the risk.
- Establish accountability. Assign an executive owner for authorization performance across departmental boundaries, with operational leaders accountable for addressing the underlying causes.
- Govern the outcomes. Review turnaround time alongside submission quality, authorization-to-claim continuity, treatment delays, and financial exposure to determine whether interventions are improving enterprise performance.
Use Leading Indicators to Protect RCM Outcomes
Prior authorization turnaround time deserves executive attention because it reveals risk while leaders still have choices to protect margin, clinical capacity, and patient access. When managed with submission quality and end-to-end continuity, it can show where payer complexity is threatening patient access, clinical capacity, workforce productivity, and reimbursement before those problems appear in downstream revenue cycle management (RCM) results.
Watch the on-demand webinar, Aligning Clinical and Coding Workflows to Reduce Prior Authorization Denials, to see how earlier clinical review, coding validation, and payer intelligence can improve authorization accuracy, reduce rework, and strengthen denial prevention.
Ali Hartnett
